Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
Clinical trial NCT05664061 · UNKNOWN
Trial details
- NCT number
- NCT05664061
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-30
- Primary completion
- 2023-07-31
- Enrollment
- 451
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.